There was no significant difference in overall survival between treatment groups , with a median overall survival of @ months ( @ % CI @-@ ) in the necitumumab plus pemetrexed and cisplatin group versus @ months ( @-@ ) in the pemetrexed and cisplatin group ( hazard ratio @ -LSB- @ % CI @-@ -RSB- ; p = @ ) .